DRUG logo

BRIGHT MINDS BIOSCIENCES INC

DRUGNASDAQ
🏆 #2818 by market capUS Equity
$57.25▲ $1.94 (+3.51%)
Latest quote
🔔
Track DRUG
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.5%
7d▲ 9.0%
14d▲ 4.3%
30d▲ 15.5%
ytd▼ 27.1%
1y▲ 0.0%
🏦Market Cap
$565M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Fair

Trading Snapshot

Day Range
$56.98 – $57.26
52-Week Range
$47.23 – $123.75
Volume (shares)
783
Avg Volume (shares)
—
Shares Outstanding
9.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-26.2
P/S Ratio
0.0x
EPS (TTM)
$-2.51
Dividend Yield
0.00%
Dilution (1yr)
+66.9%
DRUG logo

BRIGHT MINDS BIOSCIENCES INC

DRUG
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$14M▲ +393.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +369.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.8M▲ +66.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$89M▲ +$31M YoY
StockOtter · stockotter.space

About BRIGHT MINDS BIOSCIENCES INC

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
56/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy3
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2022

Latest News & Updates

News unavailable.